Mylan Ireland has entered into an agreement with Aspen Global
to acquire the US commercialization, marketing and intellectual property rights
relating to Arixtra (fondaparinux sodium) Injection and the authorized generic
(AG) of Arixtra. Arixtra is indicated to treat prophylaxis of deep vein
thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients
undergoing hip fracture surgery, including extended prophylaxis, hip
replacement surgery, knee replacement surgery or abdominal surgery who are at
risk for thromboembolic complications. Under an interim distribution
arrangement with Aspen, Mylan is already selling Arixtra in the US, while
Apotex is currently selling the AG of Arixtra, which will be transitioning to
Mylan Institutional by end of 2014.
Well, having a new product in the market or buying rights of
a new product and getting it positioned in the favor of consumer’s need could
be a gruesome process for any company. Turacoz’s Brand communication
team can plan and assist new product launch and develop strong brand
communication for your product/services to reach the target audience
effectively and efficiently.
We strongly focus on identification of target
audience/consumers, communication mediums, and the big idea of the campaign,
hitches and budget of the project. Our ground-breaking techniques to represent
drug information to the target audience will enhance the product launch and
ultimately sales within desired time line. We believe in 360 degree brand
communication which involves print, media and digital solutions for your
product branding. We create clear, innovative and interactive communication
messages.
The documents that can help in the branding or positioning Arixtra
could be any or many of the following:
Read
more at PBR
No comments:
Post a Comment